Abstract

Safety and Efficacy of Obinutuzumab Plus Fludarabine and Cyclophosphamide in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the GREEN Study

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy
Stephan Stilgenbauer ... Robin Foà
Blood | VOL. 134
Stephan Stilgenbauer, et. al.Stephan Stilgenbauer ... Robin Foà
13 Nov 2019
Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study ‘Veritas‘
Francesca Romana Mauro ...
Blood | VOL. 136
Francesca Romana Mauro, et. al.Francesca Romana Mauro ...
05 Nov 2020
The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
Hervé Tilly ...
Blood | VOL. 138
Hervé Tilly, et. al.Hervé Tilly ...
04 Dec 2021
Worldwide Examination of Patients with CLL Hospitalized for COVID-19
...
Blood | VOL. 136
, et. al. ...
05 Nov 2020
View more papers

More From: Blood

Paper Title
Journal
Date
Author
JAK2/mTOR Inhibition Fails to Prevent Acute GVHD Despite Reduced Th1/Th17 cells: Final Phase II Trial Results.
Joseph A Pidala ... Brian C Betts
Blood | VOL. -
Joseph A Pidala, et. al.Joseph A Pidala ... Brian C Betts
24 Jul 2024
Critical Role of Tripartite Fusion and LBD Truncation in Certain RARA- and all RARG-Related Atypical APL.
Xiaosu Zhou ... Hongxing Liu
Blood | VOL. -
Xiaosu Zhou, et. al.Xiaosu Zhou ... Hongxing Liu
24 Jul 2024
Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease (REACH4).
Franco Locatelli ... Christina Diaz-De-Heredia
Blood | VOL. -
Franco Locatelli, et. al.Franco Locatelli ... Christina Diaz-De-Heredia
24 Jul 2024
A predictive model for therapy failure in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy.
Xiaoshuai Zhang ... Qian Jiang
Blood | VOL. -
Xiaoshuai Zhang, et. al.Xiaoshuai Zhang ... Qian Jiang
24 Jul 2024
View more papers